524 related articles for article (PubMed ID: 24098024)
1. miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
Pichler M; Winter E; Ress AL; Bauernhofer T; Gerger A; Kiesslich T; Lax S; Samonigg H; Hoefler G
J Clin Pathol; 2014 Mar; 67(3):198-203. PubMed ID: 24098024
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
3. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
6. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
11. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.
Cappuzzo F; Sacconi A; Landi L; Ludovini V; Biagioni F; D'Incecco A; Capodanno A; Salvini J; Corgna E; Cupini S; Barbara C; Fontanini G; Crinò L; Blandino G
Clin Colorectal Cancer; 2014 Mar; 13(1):37-45.e4. PubMed ID: 24503111
[TBL] [Abstract][Full Text] [Related]
15. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
16. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
17. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor in CRC patients in the era of the RAS.
Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
